Get the Stockscreener App
4.875
8.88%
-0.475
Pre-market:
4.87
-0.005
-0.10%
Immunitybio Inc stock is traded at $4.875, with a volume of 5.02M.
It is down -8.88% in the last 24 hours and up +37.32% over the past month.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.
See More
Previous Close:
$5.35
Open:
$5.32
24h Volume:
5.02M
Relative Volume:
1.02
Market Cap:
$3.40B
Revenue:
$1.31M
Net Income/Loss:
$-597.65M
P/E Ratio:
-4.2763
EPS:
-1.14
Net Cash Flow:
$-425.62M
1W Performance:
+0.93%
1M Performance:
+37.32%
6M Performance:
-30.75%
1Y Performance:
+20.37%
1-Day Range:
$4.795
$5.33
1-Week Range:
$4.43
$5.38
52-Week Range:
$3.10
$10.53
Immunitybio Inc Stock (IBRX) Company Profile
Name
Immunitybio Inc
Sector
Industry
Phone
(844) 696-5235
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| IBRX | 4.875 | 3.40B | 1.31M | -597.65M | -425.62M | -1.14 |
| VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-03-22 | Initiated | Jefferies | Buy |
Immunitybio Inc Stock (IBRX) Latest News
ImmunityBio (IBRX) Reports Q3 Loss, Tops Revenue Estimates - MSN
ImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months - BioSpace
ImmunityBio announces new data from QUILT 3.032 study - TipRanks
Immunitybio Inc earnings beat by $0.04, revenue topped estimates - Investing.com Australia
Following recent decline, ImmunityBio, Inc.'s (NASDAQ:IBRX) top shareholder Chief Scientific Officer Patrick Soon-Shiong sees holdings value drop by 11% - Simply Wall St
ImmunityBio Inc. Reports Earnings Amid Financial Challenges - TipRanks
ImmunityBio: Q3 Earnings Snapshot - The Pioneer
ImmunityBio Inc. (IBRX) Quarterly 10-Q Report - Quartzy
Innovative Bladder Cancer Therapy Produces $6 Million in Sales - Precision Vaccinations
ImmunityBio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
ImmunityBio Reports Third-Quarter 2024 Financial Results - The Bakersfield Californian
(IBRX) Technical Pivots with Risk Controls - Stock Traders Daily
ImmunityBio (NASDAQ:IBRX) Stock Price Down 5.3%Should You Sell? - MarketBeat
Why ImmunityBio Stock Is Trading Higher Thursday - MSN
Commit To Buy ImmunityBio At $4, Earn 25% Using Options - Nasdaq
IMMUNITYBIO ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
LA Times Owner Faces Investor Suit Over Drug Co.'s Woes - Law360
Penny Stock Trades: Joby Aviation and ImmunityBio - Baystreet.ca
ImmunityBio (IBRX) Soars 26.4%: Is Further Upside Left in the Stock? - MSN
ImmunityBio (NASDAQ:IBRX) Stock Price Down 9.6%Here's Why - MarketBeat
(IBRX) Pivots Trading Plans and Risk Controls - Stock Traders Daily
ImmunityBio (IBRX) Stock Soaring on Plans to Bridge Gaps in Cancer Treatments - TipRanks
ImmunityBio: CAR-NK Cell Therapy Data For NHL Expected In Second Half Of 2025 - Seeking Alpha
Trump Media & Tech, ImmunityBio, And iRhythm Are Among Top 10 Mid Cap Gainers Last Week (Oct 21-Oct 25): Are The Others In Your Portfolio? - Benzinga
ImmunityBio (NASDAQ:IBRX) Sees Strong Trading Volume – Still a Buy? - Defense World
ImmunityBio Stock Heats Up, Catches Retail's Eye On Cancer Drug Trial Progress And Analyst’s Bullish Call - Barchart
ImmunityBio: Continued Volatility Suggests Further Upside Potential, But I'd Be Careful - Seeking Alpha
ImmunityBio (NASDAQ:IBRX) Sees Strong Trading VolumeWhat's Next? - MarketBeat
ImmunityBio stock jumps after trial update (IBRX:NASDAQ) - Seeking Alpha
Stock Traders Buy High Volume of ImmunityBio Call Options (NASDAQ:IBRX) - MarketBeat
EF Hutton sees over 600% upside in biotech small cap ImmunityBio - Kursiv Media
Top 2 Health Care Stocks That May Fall Off A Cliff This Month - Benzinga
ImmunityBio (IBRX) Stock Extends Pre-Hour Rally Following Clinical Trial News - Stocks Telegraph
ImmunityBio commences CD19 t-haNK cell therapy trial for NHL - Yahoo! Voices
ImmunityBio begins dosing in Phase 1 trial of CAR-NK therapy for relapsed NHL - World Pharmaceutical Frontiers
ImmunityBio (NASDAQ:IBRX) Rating Increased to Strong-Buy at EF Hutton Acquisition Co. I - Defense World
ImmunityBio (NASDAQ:IBRX) Trading 7.8% HigherHere's What Happened - MarketBeat
ImmunityBio Stock Could Rocket 800%, Analyst Says - Barron's
This Biotech Stock Could Rocket 800%, Analyst Says - MSN
ImmunityBio: 1st patient dosed in CAR-NK cell therapy study relapsed NHL - TipRanks
First Patients Dosed in Phase 1 Clinical Study of ImmunityBio’s CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma - Business Wire
ImmunityBio (NASDAQ:IBRX) Upgraded to Strong-Buy by EF Hutton Acquisition Co. I - MarketBeat
800% Upside For This Biotech StockAnalyst Initiates Coverage On Bladder Cancer Focused ImmunityBio - Yahoo Finance
ImmunityBio (NASDAQ:IBRX) Shares Gap UpHere's What Happened - MarketBeat
EF Hutton sets stock target with buy rating for ImmunityBio, cites cancer therapy - Investing.com
Kuehn Law Encourages Investors of ImmunityBio, Inc. to Contact L - GuruFocus.com
Layoff Tracker: Takeda Cuts More Employees, Total Exceeds 1,300 in 2024 - BioSpace
ImmunityBio to Participate in the Jefferies London Healthcare Conference - BioSpace
Immunitybio Inc Stock (IBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.69%
6.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):